Evidence map›Paper›PMID 41948728›Full record

ArticleFrontiers in pharmacology2026

Antibody conjugation of paclitaxel enables aqueous compatibility and enhances tumor-targeted efficacy

Gul E Rana, Shufan Yang, Yanting He, Chengcheng Qiu, Jing Long, Yezhen Huang, Wenjing Liu, Jincheng Luo, Jindi Zhu, Siwen Xu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gul E Rana *Biotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Shufan Yang *Biotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Yanting He *Biotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Chengcheng QiuBiotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Jing LongBiotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Yezhen HuangBiotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Wenjing LiuBiotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Jincheng LuoBiotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Jindi ZhuBiotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Siwen XuBiotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Qi WangBiotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Chun-He WangBiotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Paclitaxel (PTX) remains a widely used chemotherapeutic agent for treating diverse solid tumors, but its clinical utility is constrained by pronounced hydrophobicity, which necessitates the use of formulation surfactants and contributes to a narrow therapeutic window. To overcome these limitations, we developed a TROP2-targeted antibody-drug conjugate (ADC) designed for selective and solvent-free delivery of PTX. Methods: The ADC, designated hRS7-PTX, was generated by conjugating PTX to the humanized anti-TROP2 monoclonal antibody (hRS7) through a rationally engineered, PEGylated, protease-cleavable linker. The conjugate was characterized for its physicochemical stability, solubility, and antigen-dependent cytotoxic activity Results: hRS7-PTX demonstrated high aqueous stability and maintained favorable physicochemical properties without the need for organic co-solvents. Discussion: These findings establish hRS7-PTX as an effective, solvent-free strategy for targeted PTX delivery that expands the therapeutic index of this widely used drug. The combination of selective tumor targeting, improved tolerability, and robust antitumor activity supports the further development of hRS7-PTX for the treatment of TROP2-positive malignancies.

Indexed as

antibody-drug conjugatein vivo efficacypaclitaxelsolubilitytumor targeting

Identifiers

PMID41948728
PMCPMC13050789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.